← Russell 3000 cross-section

MYGN MYRIAD GENETICS INC

Trailing twelve months to 2026-06-30 · as filed 2026-07-31, not restated
Healthcare

Scale

Market cap
$308m
Revenue TTM
$807m
Net income TTM
$-113m
Free cash flow
Composite score
Sector rank
#2641

Valuation

P / E
EV / EBITDA
EV / sales
0.4
FCF yield
Earnings yield vs 10-yr
-41.23pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-14.0%
EBITDA margin
-6.0%
ROE
-37.0%
ROIC
-31.9%
Revenue growth
-3.2%

Insider activity, last 90 days

Net open-market
$-0.07m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Revenue The following table summarizes year-over-year revenue changes in our core product categories: The following table summarizes volume changes in our core product categories: Revenue decreased $22.4 million for the three months ended June 30, 2026 compared to the same period in the prior year. Cancer Care Continuum revenue decreased $13.6 million due to a 15% decrease in revenue per test due to declines in reimbursement and due to unfavorable changes in estimates associated primarily with orders from the first quarter of 2026, partially offset by a 6% increase in volume. …MYRIAD GENETICS INC, 10-Q, period ended 2026-06-30, filed 2026-07-31

Read the full passage →